The drug discovery business for ethical pharmaceuticals is at the core of the Kyowa Hakko Kirin Group. Our unique business structure that also incorporates biosimilars, diagnostics and bio-chemicals provides us with many business opportunities, and enables us to offset the high-risk drug discovery business. Few companies are like Kyowa Hakko Kirin, and the possibilities from synergies among our businesses are a Kyowa Hakko Kirin Group strength.
Ethical Pharmaceuticals
Focusing on the categories of nephrology, oncology, immunology/allergy and the central nervous system, we are enhancing cooperation from research and development to production, sales and marketing to rapidly evolve into a major player. We will steadily launch products from our well-stocked pipeline of development candidates while creating an effective, highly specialized sales and marketing organization with the objective of earning the trust of health care providers.
